Your Health, We Care
Release date: 2024-08-09 15:49:10 Recommended: 101
Pemigatinib is a targeted drug that is mainly used to treat cholangiocarcinoma.
From the perspective of drug specifications, Pemigatinib is available in several different dose versions to meet the treatment needs of different patients. Common sizes include 4.5mg/tablet, 9mg/tablet, and 13.5mg/tablet, and each size usually contains 14 tablets or 21 tablets (depending on the region). These different specifications of drugs have different dosages, but they all belong to the same drug ingredient Pemigatinib, but there are differences in packaging and dosage.
On April 18, 2020, the United States Food and Drug Administration (FDA) granted accelerated approval of Pemazyre (Pemigatinib) oral tablets developed by Incyte for the treatment of adult patients with treatment-experienced advanced cholangiocarcinoma. This is the world's first targeted therapy for cholangiocarcinoma.
On August 26, 2022, the FDA re-approved Pemazyre for the treatment of adults with relapsed or refractory myeloid or lymphoid tumors (MLNs) with FGFR1 rearrangements.
Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and its symptoms vary from individual to individual, and the common symptoms include jaundice, abdominal pain, fever, etc.
Jaundice is the most common symptom of cholangiocarcinoma, and about 90%~98% of cholangiocarcinoma patients have varying degrees of skin and scleral jaundancosis. Jaundice may get worse gradually and last longer. Patients with cholangiocarcinoma usually develop jaundice at an early stage, accompanied by symptoms such as itching of the skin all over the body.
About half of the patients have symptoms such as right upper abdominal distension and pain, which can radiate to the back. Abdominal pain may initially resemble symptoms of cholelithiasis or cholecystitis, followed by persistent abdominal pain.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
